Salmonella typhi ty2 vi polysaccharide antigen
As of the edition of 20 October 2026, Salmonella typhi ty2 vi polysaccharide antigen is a drug: marketed, first approved in 2000 (US); US protection ended in 2012.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Unknown
- Brand name
- Typhim Vi
- First approved
- 4 February 2000 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Sanofi
- Registered trials
- 8, 0 stopped early
- Disease areas
- Infections; Digestive system; Heart and blood vessels; Immune system; Lungs and airways; Mental health
US protection
US protection ended in 2012.
US protection ended in 2012, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Sanofi. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 8 |